Abel D. Ang
Research Subjects
Abel D. Ang has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
Aileen Sandilands
Jacqui Wood Cancer Centre, Division of Cancer Research, Ninewells Hospital and Medical School, University of Dundee , James Arrott Drive, Dundee DD1 9SY
2 shared publications- Barry D. Hock
Haematology Research Group, Department of Pathology and Biomedical Science University of Otago Christchurch New Zealand
2 shared publications Gabi U. Dachs
Mackenzie Cancer Research Group, Department of Pathology and Biomedical Science, University of Otago, Christchurch, New Zealand
2 shared publications- John David Hayes
Division of Cancer Research, School of Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee, Scotland, UK
2 shared publications - Linda A. Buss
Mackenzie Cancer Research Group, Department of Pathology and Biomedical Science, University of Otago, Christchurch, New Zealand
2 shared publications Albena T Dinkova-Kostova
Jacqui Wood Cancer Centre, Division of Cancer Research, Ninewells Hospital and Medical School, University of Dundee , James Arrott Drive, Dundee DD1 9SY
1 shared publication
Latest Publications
- Open Access
- 3 March 2026
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 118 (3)
The CNC-bZIP transcription factor Nrf2 controls expression of matrix metalloproteases in murine macrophages
Liver fibrosis is a chronic condition that often leads to organ failure. Currently, no effective treatment exists for advanced liver fibrosis. De-repression of the transcription factor Nrf2, by inhibition of the ubiquitin ligase substrate adaptor Keap1, is a promising strategy to treat liver fibrosis because Nrf2 augments cytoprotection and blunts the profibrotic TGF-β pathway. Herein, Nrf2 is reported to control matrix metalloproteinase (MMP) expression during chronic liver injury, and more specifically in macrophages, which play a key role in the resolution of fibrosis. We found impaired expression of Mmp8, Mmp9, Mmp12, and Mmp14 in the livers of Nrf2-knockout (Nrf2-ko) mice compared to wild-type (WT) mice, both basally and following CCl4 damage. Investigation of bone-marrow-derived macrophages (BMDMs) revealed profoundly impaired expression of Mmp8 and Mmp12 in Nrf2-ko BMDMs and a concomitant hyper-expression in Keap1-knockdown (Keap1-kd) BMDMs, which were corroborated by siRNA knockdown of Nrf2 and macrophage-specific conditional knockout of Nrf2. This trend was observed under basal conditions and post-efferocytosis. Total MMP activity was also found to be highest in the conditioned medium of Keap1-kd post-efferocytosis BMDMs. ChIP-seq revealed Nrf2-binding sites upstream of Mmp12, which also showed the strongest expression response to Nrf2. Lastly, through pharmacological de-repression of Nrf2, using TBE-31 to inhibit Keap1, upregulation of MMP expression was observed in BMDMs and livers of mice following acute liver injury. In conclusion, Nrf2 has been shown to be a regulator of MMP expression and activity in stimulated macrophages, which reveals a new mechanism by which Nrf2 regulates macrophage function.
- 3 March 2026
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 118 (3)
Open AccessThe CNC-bZIP transcription factor Nrf2 controls expression of matrix metalloproteases in murine macrophages
Liver fibrosis is a chronic condition that often leads to organ failure. Currently, no effective treatment exists for advanced liver fibrosis. De-repression of the transcription factor Nrf2, by inhibition of the ubiquitin ligase substrate adaptor Keap1, is a promising strategy to treat liver fibrosis because Nrf2 augments cytoprotection and blunts the profibrotic TGF-β pathway. Herein, Nrf2 is reported to control matrix metalloproteinase (MMP) expression during chronic liver injury, and more specifically in macrophages, which play a key role in the resolution of fibrosis. We found impaired expression of Mmp8, Mmp9, Mmp12, and Mmp14 in the livers of Nrf2-knockout (Nrf2-ko) mice compared to wild-type (WT) mice, both basally and following CCl4 damage. Investigation of bone-marrow-derived macrophages (BMDMs) revealed profoundly impaired expression of Mmp8 and Mmp12 in Nrf2-ko BMDMs and a concomitant hyper-expression in Keap1-knockdown (Keap1-kd) BMDMs, which were corroborated by siRNA knockdown of Nrf2 and macrophage-specific conditional knockout of Nrf2. This trend was observed under basal conditions and post-efferocytosis. Total MMP activity was also found to be highest in the conditioned medium of Keap1-kd post-efferocytosis BMDMs. ChIP-seq revealed Nrf2-binding sites upstream of Mmp12, which also showed the strongest expression response to Nrf2. Lastly, through pharmacological de-repression of Nrf2, using TBE-31 to inhibit Keap1, upregulation of MMP expression was observed in BMDMs and livers of mice following acute liver injury. In conclusion, Nrf2 has been shown to be a regulator of MMP expression and activity in stimulated macrophages, which reveals a new mechanism by which Nrf2 regulates macrophage function.
- Open Access
- 18 June 2025
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 776, 152225
CD5L is a target of transcription factor Nrf2
- 18 June 2025
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 776, 152225
Open AccessCD5L is a target of transcription factor Nrf2
- 1 November 2021
- Published by Elsevier in Immunology Letters
- Vol. 239, 60-71
Effects of exercise and anti-PD-1 on the tumour microenvironment
- 1 November 2021
- Published by Elsevier in Immunology Letters
- Vol. 239, 60-71
Effects of exercise and anti-PD-1 on the tumour microenvironment
- 1 June 2021
- Published by Elsevier in Immunology Letters
- Vol. 234, 13-15
Is the immunogenicity of PD-1 blocking antibodies a confounding variable in murine studies?
- 1 June 2021
- Published by Elsevier in Immunology Letters
- Vol. 234, 13-15
Is the immunogenicity of PD-1 blocking antibodies a confounding variable in murine studies?